{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010309","form_type":"8-K","ticker":null,"cik":"0001821323","company_name":"Sigilon Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.864911+00:00","generated_at":"2026-06-14T18:26:42.156722+00:00","sec_items":["1.02","5.03","5.07","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sigilon repays $16.4M Oxford loan early; files 1-for-13 reverse stock split","bullets":["Repaid $16.4M to Oxford Finance for $20M term loan; all obligations terminated.","Cash and marketable securities of $56.4M as of March 31 expected to fund operations into 2025.","Stockholders approved 1-for-13 reverse stock split effective May 23, 2023.","Directors Douglas Cole and Stephen Oesterle elected; PricewaterhouseCoopers ratified as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010309","json":"https://secwatch.observer/filing/0001558370-23-010309.json","markdown":"https://secwatch.observer/filing/0001558370-23-010309.md","text":"https://secwatch.observer/filing/0001558370-23-010309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/sgtx-20230519x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:26:42.156722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34574c93d4b0ac08f73a893c1e8dd3a5f014d120","claim":"Sigilon Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-13 reverse stock split (effective 2023-05-22).","evidence_excerpt":"On May 22, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-13.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-22"}],"fact_type":"governance_change"},{"claim_id":"f696d0e639dc59d00b5b303b6361ff763470caba","claim":"Sigilon Therapeutics, Inc. terminated Loan and Security Agreement with Oxford Finance LLC, as collateral agent for the Lenders valued at $16.4 million (effective 2023-05-19).","evidence_excerpt":"On May 19, 2023, Sigilon Therapeutics, Inc. (the “Company”) voluntarily repaid all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to $16.4 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement dated as of September 2, 2020","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC, as collateral agent for the Lenders"},{"label":"Value","value":"$16.4 million"},{"label":"Effective","value":"2023-05-19"}],"fact_type":"material_agreement"},{"claim_id":"3297ead2a61831361922970c240383dcc8a95136","claim":"Sigilon Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company's Fifth Amended and Restated Certificate of Incorporation at the 2023-05-19 meeting.","evidence_excerpt":"Proposal 2: Approval of an Amendment to the Company's Fifth Amended and Restated Certificate of Incorporation. The stockholders of the Company approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding Common Stock at any whole number ratio between, and inclusive of, one-for-eight and one-for-30. The results of the vote were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 28,979,926 ​ 378,323 ​ 31,717","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"cdb5ec66191c08635d8c1cf14a4fe055e27d6509","claim":"Sigilon Therapeutics, Inc. shareholders approved Ratification of the Company’s Independent Registered Public Accounting Firm at the 2023-05-19 meeting.","evidence_excerpt":"Proposal 3: Ratification of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023. The results of the vote were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 29,313,965 ​ 43,976 ​ 32,025","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"e18660a07074fae23f5389d75ffa36cf65e22e6c","claim":"Sigilon Therapeutics, Inc. shareholders approved Election of Directors at the 2023-05-19 meeting.","evidence_excerpt":"Proposal 1: Election of Directors The stockholders of the Company elected the director nominees listed below to serve on the Company’s Board of Directors as members of Class III for a term of three years. The results of the vote were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Name of Nominee For Against Abstain Broker Non-Votes Douglas Cole, M.D. ​ 23,459,263 ​ 3,294,129 ​ 37,031 ​ 2,599,543 Stephen Oesterle, M.D. ​ 23,654,738 ​ 3,095,809 ​ 39,876 ​ 2,599,543","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}